Plasma Phosphorylated <scp>Tau181</scp> as a Biomarker for Alzheimer's Disease Co‐Pathology in Lewy Body Disease
Plasma pTau181 reflects amyloid and tau pathology but not α-synuclein pathology in LBD. Plasma pTau181 is a useful indicator for neurodegeneration in cortical regions vulnerable to NFT pathology and adds value in identifying AD co-pathology. These findings support plasma pTau181 as a cost-effective screening tool for AD co-pathology in LBD. © 2025 International Parkinson and Movement Disorder Society.
Authors
- Hadia Fatima
- Keith A. Johnson (ORCID: https://orcid.org/0000-0002-4685-5173)
- Stephen N. Gomperts (ORCID: https://orcid.org/0000-0002-0083-0077)
- Anna E. Goodheart
- Emma G. Thibault (ORCID: https://orcid.org/0000-0002-7873-742X)
- Pia Kivisäkk (ORCID: https://orcid.org/0000-0001-9708-7509)
- Michael J Properzi (ORCID: https://orcid.org/0000-0001-7855-2372)
- Steven Edward Arnold (ORCID: https://orcid.org/0000-0002-9487-415X)
- Erin Peterec
- Rong Ye (ORCID: https://orcid.org/0000-0003-3855-567X)
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Movement Disorders
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1002/mds.30238
- Citations
- 2
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- U.S. Department of Defense
- Michael J. Fox Foundation for Parkinson's Research
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke